Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Deerfield Management ... Healthcare Innovations Fund, L.P., which will invest in groundbreaking ... in genetic diseases, cancer, and orphan diseases. The venture ... transform how therapeutics are developed and improve the way ... one of the largest healthcare-focused venture funds in the ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... SINGAPORE , July 28, 2015  Faced ... treatments that are palliative rather than symptomatic, the ... With few existing therapies capable of curing or ... providers are starting to look towards regenerative medicine ... represents a new paradigm in human health with ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... of the equation , ,Identity theft has seen the ... three years. The United States is faced with an ever-changing ... both sides of the equation, organizational and consumer. , ... to a new report from the Federal Trade Commission (FTC). ...
... pioneer company looks to reclaim lost ground , ,CHIPPEWA FALLS, ... operating out of offices on Lowater Road here in its hometown, ... wonderful heights. , ,With its next-generation X1, on the market since ... toward the future with a twinkle in its corporate eye that, ...
... often been regarded as the economic motor of the European ... of Scandinavia, to the east of the U.K. and France, ... the east European countries of Poland, the Czech Republic and ... not only one of Europes largest populations but considering ...
Cached Biology Technology:Are You Ready for Identity Theft? 2Are You Ready for Identity Theft? 3Are You Ready for Identity Theft? 4Are You Ready for Identity Theft? 5Are You Ready for Identity Theft? 6Are You Ready for Identity Theft? 7Cray Rides Again 2Cray Rides Again 3German Life Science Oktoberfest Comes to the Midwest 2German Life Science Oktoberfest Comes to the Midwest 3German Life Science Oktoberfest Comes to the Midwest 4German Life Science Oktoberfest Comes to the Midwest 5German Life Science Oktoberfest Comes to the Midwest 6
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... ARBOR, Mich.A new power scheme for cardiac pacemakers turns ... Engineering researchers at the University of Michigan designed ... heartbeats through the chest and converts it to electricity ... mini-medical machines send electrical signals to the heart to ...
... of the shark and are often removed from the body, which ... many countries allow the fins to be landed detached from shark ... cent of the total shark catch. New University of British Columbia ... A study published this week in the journal Fish ...
... are a rarely collected group of insects. Adults are considered ... of juvenile spiders. Eight genera are recorded in Australasia, including ... of large, hairy, often metallic coloured adults whose larvae specialize ... and funnel web spiders. In this study, four ...
Cached Biology News:Heart-powered pacemaker could one day eliminate battery-replacement surgery 2Law that regulates shark fishery is too liberal: UBC study 2
... observations of cell cultures under precise, controlled ... strain parameters in addition to a microscope ... chamber used by the ST-195 is compatible ... can be used with Nikon, Olympus, Leica, ...
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
... carrier proteins to simplify the production ... Carrier Proteins are commonly used carriers ... heterobifunctional cross-linker (Sulfo-SMCC). This activation results ... Thus allowing the maleimide-activated carrier ...
Biology Products: